Novo Nordisk (0QIU) Price & Analysis

Compare

65 Followers

0QIU Stock Chart & Stats

Day’s Range― - ―

52-Week Rangekr287.55 - kr942.40

Previous CloseN/A

Volume862.13K

Average Volume (3M)2.32M

Market Cap

kr1.59T

Enterprise Valuekr2.04T

Total Cash (Recent Filing)kr41.55B

Total Debt (Recent Filing)kr118.72B

Price to Earnings (P/E)14.4

Beta1.12

Next Earnings

Nov 05, 2025

EPS Estimate

6.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)5.96

Shares Outstanding3,390,128,000

10 Day Avg. Volume2,642,807

30 Day Avg. Volume2,321,817

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr468.62

Price Target Upside29.54% Upside

Rating ConsensusHold

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Product Mix ImpactMore visibility on product mix with positive impact related to 340B, mostly from Ozempic with remainder being insulin, which explains NovoRapid and Tresiba beats.

ValuationAnalyst recommends maintaining a Buy rating on Novo Nordisk due to its valuation, with the company trading at a c10-year low on PE despite continued forward double-digit sales CAGR.

Bears Say

China Market PerformanceSofter performance in China driven by destocking, mostly for Ozempic, with variability also seen for Wegovy.

Growth UncertaintyUncertain path to recovery for Wegovy and Ozempic, with further headwinds that could limit growth.

Trading PressureThe growth outlook dominates the debate with increasing pressure expected around trading PE multiple into the sema patent cliff.

Novo Nordisk News

Bullish flow in Novo Nordisk with shares up 1.45%

Bullish flow in Novo Nordisk (NVO), with shares up 80c, or 1.45%, near $56.15. Options volume relatively light...

4d ago

NVO

Mixed options sentiment in Novo Nordisk with shares down 1.8%

Mixed options sentiment in Novo Nordisk (NVO), with shares down $1.01 near $55.33. Options volume relatively light with...

4d ago

NVO

Nvidia reportedly stops H20 AI chip output for China: Morning Buzz

The major averages were sharply higher near noon as U.S. Federal Reserve Chair Jay Powell said in his...

9d ago

Mixed options sentiment in Novo Nordisk with shares up 2.79%

Mixed options sentiment in Novo Nordisk (NVO), with shares up $1.54, or 2.79%, near $56.99. Options volume roughly...

9d ago

NVO

Cat hair, bacteria found at Novo Nordisk plant during inspection, STAT reports

Cat hair, pests, bacteria, and equipment failures were among the concerns of a recent regulatory inspection of a...

9d ago

NVO

Novo Nordisk upgraded to Hold from Sell at DBS Bank

DBS Bank analyst Nico Chen upgraded Novo Nordisk (NVO) to Hold from Sell with a DKK 340 price...

9d ago

NVO

Novo Nordisk freezes non-critical hiring, Reuters reports

Novo Nordisk (NVO) has implemented a global hiring freeze covering job roles that are not critical for its...

11d ago

NVO

Viking Therapeutics drop may be partially ‘sell the news,’ says H.C. Wainwright

After Viking Therapeutics (VKTX) announced topline results from its Phase 2 trial of oral VK2735 for weight loss,...

12d ago

LLY

NVO

Eli Lilly, Novo Nordisk up 2% each after Viking obesity pill trial results

Shares of Eli Lilly (LLY) are up $11.11, or about 2%, to $709.29 in pre-market trading while those...

12d ago

LLY

NVO

Novo Nordisk price target lowered to $70 from $105 at TD Cowen

TD Cowen analyst Michael Nedelcovych lowered the firm’s price target on Novo Nordisk (NVO) to $70 from $105...

12d ago

NVO

Novo Nordisk’s Strategic Focus on Obesity Market and Oral Semaglutide Drives Buy Rating

In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk, with...

12d ago

NVO

Novo Nordisk Faces Uncertainty Amid Revenue Guidance Adjustment and Leadership Transition

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk today and set a price target...

17d ago

NVO

Cautious Hold Rating on Novo Nordisk Amid Profit Warning and Legal Challenges

Bank of America Securities analyst Sachin Jain maintained a Hold rating on Novo Nordisk yesterday and set a...

24d ago

NVO

Novo Nordisk Faces Legal Storm Over Misleading Projections

Novo Nordisk A/S is facing a significant legal challenge as a class action lawsuit has been filed against...

27d ago

NVO

0QIU FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest share price was kr287.55 and its highest was kr942.40 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is kr1.59T.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Nov 05, 2025 which is in 66 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Aug 06, 2025. The company reported kr5.96 earnings per share for the quarter, beating the consensus estimate of kr5.933 by kr0.027.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk does not currently pay dividends.

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 6.05.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of kr5.96 in its last earnings report, beating expectations of kr5.933. Following the earnings report the stock price went down -4.442%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in GB:0QIU

Company Description

Novo Nordisk

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (0QIU) Earnings & Revenues

Historic Earnings Reports

0QIU Stock 12 Month Forecast

Average Price Target

kr468.62

▲(29.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"299":"kr299","900":"kr900","449.25":"kr449.3","599.5":"kr599.5","749.75":"kr749.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":620,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr620.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":468.62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr468.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":340,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr340.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[299,449.25,599.5,749.75,900],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,300.16,324.76307692307694,349.36615384615385,373.96923076923076,398.57230769230773,423.1753846153846,447.77846153846156,472.38153846153847,496.9846153846154,521.5876923076924,546.1907692307692,570.7938461538461,595.396923076923,{"y":620,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,300.16,313.1184615384616,326.0769230769231,339.03538461538466,351.99384615384616,364.9523076923077,377.91076923076923,390.8692307692308,403.8276923076923,416.78615384615387,429.7446153846154,442.70307692307694,455.6615384615385,{"y":468.62,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,300.16,303.2246153846154,306.2892307692308,309.3538461538462,312.41846153846154,315.48307692307696,318.54769230769233,321.6123076923077,324.67692307692306,327.7415384615385,330.80615384615385,333.8707692307692,336.93538461538463,{"y":340,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":886.89,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":899.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":776,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":748.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":746.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":604.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":594.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":623.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":427.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >